Introduction
============

Nowadays, chronic obstructive pulmonary disease (COPD) is considered a major cause of morbidity and mortality worldwide. In contrast to the trend for cardiovascular diseases, cancer and stroke, death rates from COPD have been rising steadily over the last decade ([@b17-copd-2-567]) and, according to estimates of the World Health Organization (WHO), by 2020 this condition shall become the third most frequent cause of death, following coronary and cerebrovascular disease ([@b24-copd-2-567]).

Although these figures on COPD morbidity and mortality are alarming, they are only a "tip of the iceberg" because COPD is often part of a much more complex profile of comorbidities ([@b14-copd-2-567]).

Over the last few years, there has been an increased awareness about the systemic nature of COPD ([@b3-copd-2-567]; [@b28-copd-2-567]) and the frequent and important chronic comorbidities that may contribute significantly to its severity and mortality ([@b33-copd-2-567]; [@b5-copd-2-567]; [@b29-copd-2-567]; [@b31-copd-2-567]), and that might be affected by treatment ([@b20-copd-2-567]; [@b30-copd-2-567]).

Several studies suggest that cardiovascular diseases (CVD) are more frequent in COPD patients than in the general population and may represent a burden greater than that of lung disease itself ([@b6-copd-2-567]; [@b15-copd-2-567]; [@b16-copd-2-567]). Moreover, Antonelli and colleagues documented that in the presence of ischemic heart diseases CVD becomes an important factor, predicting all-cause mortality on COPD patients ([@b2-copd-2-567]).

In addition, among COPD comorbidity, depression deserves particular attention. COPD (especially at severe levels) leads to impairments in activities of daily living, social and psychological functioning and recreational activities. Depression has been found to occur in 7%--42% of COPD patients up to four times more frequently than in subjects without COPD ([@b19-copd-2-567]).

These observations highlight the fragmentary nature of available information, and at the same time the importance of studying COPD comprehensively, considering often-associated concomitant conditions and quantifying the burden of illness that these conditions cause in this population.

With this study we intend to identify a population suffering from COPD, assessing COPD prevalence in a large sample of Italian population (about 8 millions of inhabitants) and describing the general profile of COPD patients, in whom comorbidity plays an important role.

Methods
=======

This is an epidemiological cross-sectional study, conducted using administrative heath services databases from 22 Italian Local Health Units (LHU) participating in the ARNO project ([@b7-copd-2-567]). The population comprised 7,731,628 inhabitants. The observation was carried out between January 1st and December 31st, 2004.

Data sources
------------

This study used the outpatients' prescriptions database (PD) of drugs totally or partially reimbursed by the National Health System (NHS), and the Civil Registry Database (CRD), in each LHU.

These databases have been extensively used for epidemiological studies including drug-exposure and chronic disease ([@b7-copd-2-567]; [@b1-copd-2-567]) as well as to study population-based health outcomes ([@b22-copd-2-567]; [@b22-copd-2-567]). Besides, the use of this source limits bias selection as these databases cover the whole population. 69% of residents were eligible for outpatient prescription drug benefits.

All databases are managed by the Consorzio Interuniversitario CINECA.

Cohort definition
-----------------

COPD cohort was identified using the following criteria: Age of 45 years or above;Chronic treatment with drugs for obstructive pulmonary diseases (inhaled/oral bronchodilators, inhaled steroids or fixed-dose combinations) (index drugs).

Chronicity was defined linking the number of prescribed packages and the duration of therapy, defined in terms of time from first to last prescription of the index drug. Patients who received more than five boxes of the index drug for over 3 months or more were considered chronically treated.

A treatment with antibiotics and/or oral steroids was assumed as an indicator of disease exacerbations.

To assess the presence of comorbidities, the prescriptions of drugs different from those for COPD were analysed. In particular, we focused on three drugs classes identifying specific co-morbidities: diabetes (insulin, insulin analogues and oral hypoglycaemic therapy), cardiovascular diseases (any cardiovascular drug) and depression (selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, monoamine uptake inhibitors).

Treatment chronicity was explored for cardiovascular and antidepressant drugs, assuming as chronic any treatment with more than three boxes over 3 or more months.

Statistical analysis
--------------------

We used descriptive statistics to examine the epidemiological and therapeutic characteristics of our sample. Prevalence of estimated COPD was defined as the number of patients receiving one or more COPD index drugs per 100 individuals in the population. Prevalence rates, as well as percentages of patients with comorbidities have been stratified by age and gender.

Results
=======

Among the population examined of 7,731,628 NHS users, 3,535,371 (46%) were of 45 years and over. Of these, 462,894 (13%) patients were exposed to at least one respiratory agent (COPD index drug). The composition of these two populations is reported in [Table 1](#t1-copd-2-567){ref-type="table"}.

On the basis of the criteria above described and the flow-chart represented in [Figure 1](#f1-copd-2-567){ref-type="fig"}, a cohort of 126,283 COPD patients was identified.

The prevalence of COPD in our adult population (≥45 years) was 3.6% and it increased greatly with age (1.9% in the age group 45--64, 4.8% in 65--74, 6.8% in 75--84 and 5.6% in ≥85 years). COPD appeared more common in males than in females (4.1% in males and 3.1% in females). This difference was particularly evident in the age group 75--84 years, while in the youngest there was no gender difference ([Figure 2](#f2-copd-2-567){ref-type="fig"}).

Main characteristics of the patients
------------------------------------

[Table 2](#t2-copd-2-567){ref-type="table"} reports the main characteristics of COPD patients including pharmacological treatment and general clinical profile.

The cohort with COPD was older than the reference population (see [Table 1](#t1-copd-2-567){ref-type="table"}). Almost 70% of the patients (88,261) were 65 or older, including 8% ≥85 years. The mean age was 70 years. Fifty-two percent (65,869) were male.

A high proportion of patients (80%) received a poly-therapy as COPD treatment, and, in particular, 67,822 patients (54%) received more than three different drugs.

Likewise, about 80% (100,430 patients) were treated with drugs indicating exacerbations. Antibiotic treatment (with or without oral corticosteroids) was the most common: three fourths of the patients (94,869) were prescribed these drugs.

Comorbidities therapy
---------------------

Ninety-eight percent of COPD patients (123,603) received at least one prescription of "non-respiratory drugs"; the main therapeutic classes used are presented in [Table 3](#t3-copd-2-567){ref-type="table"}. These data highlight the clinical complexity of the COPD population, highly exposed to different pharmacological agents, from antibiotic or cardiovascular drugs (more than 70%) to nervous system agents (24%).

Considering specific comorbid conditions such as cardiovascular disease, diabetes and depression and applying the chronicity criteria for therapy quoted above (see Method section), 86,351 patients (68.4% of COPD patients) suffered from at least one of these conditions.

Cardiovascular diseases, as expected in these age groups, were the most common condition coexisting in COPD patients (80,840 pts, 64.4%). 17,091 subjects were treated for diabetes (12.4% of COPD patients) and 10,292 for depression (8%). The percentage of patients suffering from these conditions increased with age ([Figure 3](#f3-copd-2-567){ref-type="fig"}).

This is particularly evident for cardiovascular diseases (about 40% in the age group 45--64 and over 80% in those ≥85 years); the same is true also for depression (6.2% among patients 45--64 years old and 10.8% among those ≥85 years) ([Figure 3](#f3-copd-2-567){ref-type="fig"}). Although overall depression was more common in females than in males (5.9% in males and 10.6% in females), the increase with age was more marked among male patients (from 3.9% to 8.2% in male vs from 8.3% to 12.8 in female) ([Figure 3](#f3-copd-2-567){ref-type="fig"}). A less remarkable increase was observed for diabetes (9.2% in the age group 45--64 and 13.7% in ≥85 years) without important gender differences ([Figure 3](#f3-copd-2-567){ref-type="fig"}). Interestingly, about 16% of COPD subjects (19,168 patients) had two out of the three considered comorbid conditions and 1352 patients (1.1%) all three. The details of the different combinations are reported in [Table 4](#t4-copd-2-567){ref-type="table"}.

These data document that about twenty thousand patients with impaired pulmonary function had a high risk profile for the spectrum of comorbid diseases. The percentage of patients with the most complex profile (all three diseases considered) indeed increased with age (0.5% of COPD patients 45--64 years old, 1.1% of 65--74, 1.4% of 75--84 and 1.5% of patients ≥85 years). This increase was particularly evident in the female population (from 0.6% in younger patients to 2.0% in older ones) ([Figure 4](#f4-copd-2-567){ref-type="fig"}).

Discussion
==========

The first and very important result of our study was the size of the sample identified, 126,283 COPD patients, that was higher than any published COPD epidemiological studies ([@b13-copd-2-567]), allowing the quantification of the burden of COPD in the community setting, through an appraisal of the "real dimension" of the problem.

This wide sample of COPD patients, identified through a different methodology respect to the most recent surveys ([@b18-copd-2-567]; [@b21-copd-2-567]), made possible to have numerically significant subgroups, generally excluded in randomized clinical trials and not particularly represented in surveys: specifically, elderly subjects (up to 11,000 patients older than 85 years), patients with multiple comorbidities (almost 20,000 patients chronically treated for at least two comorbid conditions); elderly females with very complex profile (814 patients with the three comorbidities considered).

These results are in agreement with the recent recommendations ([@b8-copd-2-567]; [@b10-copd-2-567]) advocating efforts to characterize the spectrum of comorbid diseases and to develop a more comprehensive approach both in the study and in the management of COPD patients. In fact, despite the advances in the care of individuals with COPD, some uncertainty remains about how best to manage patients, particularly elderly, with different chronic diseases. The information is limited and available studies tend to exclude patients with complex comorbidity ([@b5-copd-2-567]; [@b10-copd-2-567]).

In our population we found that nearly all (98%) received other drugs besides respiratory agents. Antibiotic agents were the most common owing to the frequent bacterial infections occurring in these patients, but the high exposure to cardiovascular, anti-inflammatory, gastrointestinal agents highlights the frequent presence of different diseases in the same patient.

Our study has, however, some limitations. Administrative databases lack clinical and diagnostic information. We identified COPD patients and comorbidities only by prescription patterns and the distinction between COPD and asthma is difficult in this context.

We limited misdiagnosis by including only subjects 45 years or older and requiring more than occasional treatment. Misdiagnosis, therefore, certainly exists in our study but likely represents only a small portion of examined population.

Another limitation is that COPD may be under-diagnosed and therefore under-treated ([@b26-copd-2-567]). Symptomatic and more severe patients are more likely to be chronically treated. Although the use of a general population protects from selection bias, our cohort likely comprised mostly patients with clear COPD, since we considered only intensive drug exposure (about 80% of patients received two or more index drugs).

In people aged 45 years and older, we measured a COPD prevalence of 3.6%. These estimates could seem to be lower than those obtained in other population-based studies of COPD.

In Italy, Viegi and colleagues measured respectively a general COPD prevalence of 12.2%, 57.0% and 28.7% using three different COPD definitions (ERS, ATS and clinical) ([@b34-copd-2-567]). However, this study included patients of every severity stage. Considering only moderate/severe COPD, the Viegi study rates result very similar to our data: 3.6%, 5.2% and 4.4% respectively.

Our estimate is also lower than the range of 4%--10% derived from an international review of COPD prevalence ([@b13-copd-2-567]), and than prevalence reported in the other European studies. In Greek people older than 35 years, Tzanakis reported a prevalence of 8.4% ([@b32-copd-2-567]); in IBERPOC, a multicenter survey in Spain ([@b25-copd-2-567]), the prevalence was 13.1% for men and 10.5% for women. The explanation of these differences lies in the variety of criteria used to define COPD.

The data available come from studies ad hoc with actively screened patients (using diagnostic methods, like spirometry), while our data derive from an analysis of treatment specifically of chronically treated patients.

If we apply less strict criteria, excluding chronicity or considering only older patients, our prevalence estimates increase and become very close to literature estimates (see [Table 1](#t1-copd-2-567){ref-type="table"}).

With respect to specific chronic comorbidities such as diabetes and cardiovascular diseases, our data are in perfect agreement with the literature. A recent study using administrative databases and identifying COPD patients according to our criteria, found a diabetes prevalence of 14.5% ([@b8-copd-2-567]); Gudmundsson and colleagues ([@b12-copd-2-567]) reported a prevalence of 10.6% and 65% for diabetes and cardiovascular disease respectively.

On the contrary, our results on depression are difficult to compare because of the wide variability in the available prevalence estimates (up to 42% in moderate to severe COPD, [@b36-copd-2-567]; [@b19-copd-2-567]), even if van Manen et al who investigated prevalence of comorbidity in patients with COPD over 40 years of age ([@b33-copd-2-567]), found a depression prevalence of 8.7%, very similar to our data.

In summary, this study, besides confirming previous evidence, documents that COPD is a health problem also in Italy and that public awareness of its burden is important. From a broader perspective, it highlights the complex spectrum of comorbidities in COPD patients, underlining the importance of a comprehensive approach in their management. Redelmeier and colleagues demonstrated that when the central focus of care is a serious condition, the care for other chronic disorders is compromised ([@b27-copd-2-567]). This could be a real problem considering the high frequency of chronic comorbidities that may drastically worsen COPD severity and mortality and of complex elderly patients, whose management is still uncertain ([@b10-copd-2-567]).

In conclusion, we think that comorbidities should be considered when estimating the social and economic burden of disease and we hope that our results will increase the attention and the initiatives on COPD, possibly in agreement with more general actions on respiratory illness ([@b35-copd-2-567]) and chronic diseases ([@b9-copd-2-567]).
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###### 

General description of the examined population

               **Population (≥45 years)**   **Patients exposed to ≥1 respiratory drugs**                 
  ------------ ---------------------------- ---------------------------------------------- ------------- ---------
  **Gender**   **N pts**                    **%**                                          **N pts**     **%**
    Male       1,603,364                    45                                             205,711       44
    Female     1,932,007                    55                                             257,183       56
  **Age**                                                                                                
    45--64     1,965,547                    56                                             207,721       45
    65--74     810,721                      23                                             128,398       28
    75--84     571,129                      16                                             99,174        21
    ≥85        187,974                      5                                              27,601        6
  **Total**    **3,535,371**                **100**                                        **462,894**   **100**

###### 

Main characteristics of COPD patients

  **Characteristics**                                 **N pts (126,283)**   **%**
  --------------------------------------------------- --------------------- -------
  **Gender**                                                                
    male                                              65,869                52.2
    female                                            60,414                47.8
  **Age, yrs**                                                              
    45--64                                            38,022                30.1
    65--74                                            38,775                30.7
    75--84                                            38,929                30.8
    ≥85                                               10,557                8.4
  **Therapy with index drug**                                               
    mono-therapy                                      25,778                20.4
    poly-therapy                                      100,505               79.6
  **Antibiotic agent -- oral steroid prescription**                         
    yes                                               100,430               79.5
  **Non-index drug prescription**                                           
    yes                                               123,603               97.9
  **Specific comorbid condition**                                           
    yes                                               86,351                68.4

###### 

Main therapeutic classes prescribed to COPD patients

  **Therapeutic class**                      **Patients**   **% of COPD pts**
  ------------------------------------------ -------------- -------------------
  Antibiotic agents                          95,845         75.9
  Cardiovascular drugs                       92,367         73.1
  Gastrointestinal and metabolic disorders   75,303         59.6
  Musculoskeletal system                     71,384         56.5
  Blood and lymphatic system                 55,922         44.3
  Endocrine system                           53,692         42.5
  Nervous system                             30,248         24.0

###### 

Detail of chronic comorbidities in COPD patients

  **Comorbidities**                **N pts**    **% of COPD pts**
  -------------------------------- ------------ -------------------
  **-- Only one**                  **65,831**   **52.1**
    Cardiovascular diseases (CV)   60,500       47.9
    Diabetes                       2,711        2.1
    Depression                     2,620        2.1
  **--Two**                        **19,168**   **15.2**
    Diabetes + CV                  12,848       10.2
    CV + Depression                6,140        4.9
    Diabetes + Depression          180          0.1
  **--Three**                      **1,352**    **1.1**
    Diabetes + CV + Depression     1,352        1.1
  **Total**                        **86,351**   **68.4**
